Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305666 | 0.87 | CYP19A1 (0.55) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL3235402 | 0.86 | NPC1 (0.72) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL305487 | 0.85 | CYP19A1 (0.76) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL10222065 | 0.84 | TSHR (0.58) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL306245 | 0.79 | CYP19A1 (0.76) | KDM4EALDH1A1CYP19A1STSHDAC1 | |
| SCHEMBL10172574 | 0.77 | CYP19A1 (0.47) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL305406 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL9491438 | 0.75 | FFAR1 (0.68) | LMNAFFAR1FFAR4HDAC6 | |
| SCHEMBL307005 | 0.75 | CYP19A1 (0.66) | SMN1; SMN2LMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL9403761 | 0.74 | LMNA (0.68) | RAB9ALMNATP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1966166-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | Sterix Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | SMN1; SMN2 4723/4885NPC1 4197/4885RAB9A 2155/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | SMN1; SMN2 3617/4885NPC1 3132/4885RAB9A 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.